Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study

Atezolizumab plus bevacizumab is the standard of care for advanced hepatocellular carcinoma (HCC) in the first-line setting, although was only evaluated in patients with Child-Pugh (CP) A liver function in the IMbrave150 trial. We sought to determine the outcomes of these patients based on CP score...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2024-11, Vol.29 (11), p.986-996
Hauptverfasser:	Storandt, Michael H, Zemla, Tyler J, Patell, Kanchi, Naleid, Nikolas, Gile, Jennifer J, Tran, Nguyen H, Chakrabarti, Sakti, Jin, Zhaohui, Borad, Mitesh, Mahipal, Amit
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab - administration & dosage Bevacizumab - therapeutic use Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology Cohort Studies Female Hepatobiliary Humans Liver Neoplasms - drug therapy Liver Neoplasms - mortality Liver Neoplasms - pathology Male Middle Aged
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!